A comprehensive review of global clinical trials for cerebral palsy has been released, offering a detailed analysis of the current research landscape. The "Cerebral Palsy - Global Clinical Trials Review, 2024" report provides insights into trial numbers, enrollment trends, and key players in the field.
The report covers a wide range of parameters, including clinical trials categorized by region, country (G7 & E7), phase, trial status, endpoint status, and sponsor type. It also identifies prominent drugs currently under investigation for cerebral palsy treatment.
Key Findings
The review highlights top companies involved in cerebral palsy therapeutics clinical trials, such as Ipsen SA, AbbVie Inc, Merz Pharma GmbH & Co KgaA, ICON Plc, Medytox Inc, Parexel International Corp, Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, LG Chem Ltd and Supernus Pharmaceuticals Inc. The report also enlists all trials (Trial title, Phase, and Status) pertaining to the company.
Furthermore, the report analyzes unaccomplished trials (terminated, suspended, and withdrawn) and provides reasons for their discontinuation. Enrollment trends over the past five years are also examined, offering a historical perspective on clinical trial activity.
Regional Analysis
The report includes a breakdown of clinical trials by region, including Asia-Pacific, Europe, North America, the Middle East and Africa, and Central and South America. It identifies the top five countries contributing to clinical trials in each region.
For G7 and E7 countries, the report provides data on the proportion of cerebral palsy trials compared to central nervous system trials, as well as breakdowns by phase and trial status.
Strategic Implications
The "Cerebral Palsy - Global Clinical Trials Review, 2024" is designed to assist stakeholders in formulating key business strategies, identifying optimal locations for conducting clinical trials, and understanding trial success rates. It also facilitates clinical trial assessment at a global, regional, and country level.
